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ABSTRACT 
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune syndrome 
in young women that is often accompanied by an ovarian teratoma (NMDAR-E 
teratoma).  A prevailing theory implicates that the generation of auto-antibodies to 
NMDAR on neurons in the central nervous system is triggered by neuroglial tissue in 
the associated teratoma.  The histopathology of NMDAR-E teratomas has not been fully 
elucidated but limited studies have focused on alterations in neuroglial tissues and 
immune cell populations.  We hypothesized that evidence of antibody generation in 
NMDAR-E teratomas could be detected by co-localized neuroglial tissue and lymphoid 
aggregates with germinal centers as well as by alterations in the composition and 
morphology of neuroglial tissues.  The study compared 12 NMDAR-E teratomas (11 
ovarian, 1 mediastinal)  to 61 control teratomas containing neuroglial tissue from women 
without NMDAR-E.  NMDAR-E teratomas were significantly smaller and were 
composed of a higher percentage of neuroglial tissue than control teratomas. Many 
NMDAR-E teratomas did not exhibit typical gross pathologic features of a mature cystic 
teratoma, but were composed of predominately solid tissue (so-called Rokitansky 
nodule).  Co-localized neuroglial tissue and lymphoid aggregates with germinal centers 
were present in 11/12 NMDAR-E teratomas, predominantly within the Rokitansky 
nodule, but only in 4/61 control teratomas (p<0.0001).  There was a relative paucity of 
mature neurons in NMDAR-E teratomas as well as a hypercellular astrocyte population, 
while there were less prominent or no differences in the presence or composition of 
diffuse inflammatory infiltrates, lymphoid aggregates without germinal centers, ganglion 
cell clusters or oligodendrocytes between NMDAR-E teratomas and control teratomas.  
We conclude that the presence of co-localized neuroglial tissue and lymphoid 
aggregates with germinal centers along with a general paucity of neurons should 
prompt clinical consideration for NMDAR encephalitis even in asymptomatic women, 
since the symptoms may occasionally develop after an otherwise incidental 
oophorectomy.   Tissue sampling should be directed to the Rokitansky nodule, when 
present, to identify neuroglial tissues; complete microscopic examination of the ovarian 
specimen should be considered if gross pathologic features of teratoma are not present.   
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The significance of the altered neuroglial cell populations and potential relationship to 
the pathogenesis of NMDAR encephalitis merit further study.  
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INTRODUCTION 
 
Anti-N-methyl-D-Aspartate receptor (NMDAR) encephalitis is an autoimmune syndrome 
defined by the presence of antibodies to NMDA receptor, a neuronal cell-surface ligand-
gated cation channel involved in glutamatergic synaptic transmission. Neurologic 
symptoms often initially manifest as confusion, agitation and personality changes but 
then rapidly progress to psychosis, dyskinesia, seizures, autonomic instability and 
respiratory collapse.[1, 2]  The syndrome predominantly affects young women and is 
often designated as a paraneoplastic syndrome because an ovarian teratoma has been 
detected in about half of affected women; rare cases of primary extra-gonadal teratoma 
or carcinoma have also been described in this syndrome.[3] Nearly all of these tumors 
contain a component of mature or immature neuroglial tissue, a finding that is slightly 
less common in control ovarian teratomas in women without encephalitis.  Reduction of 
the anti-NMDAR antibody titer following immunotherapy and surgical removal of the 
ovarian tumor, if present, is associated with clinical improvement in most patients.[2, 4]   
 
Based on these observations, a paraneoplastic mechanism of disease has been 
proposed:  disruption of immunologic self-tolerance to NMDAR expressed by neuroglial 
tissue in the ovarian teratoma results in abnormal production and circulation of NMDAR 
antibodies that subsequently enter the CNS, leading to  encephalitis.[5, 6]  The 
mechanism for a break in immune tolerance is unclear but triggering events such as 
viral infection or genetic predisposition have been proposed [7, 8].  A paraneoplastic 
mechanism of disease may not explain all cases of this syndrome, since some patients 
do not have a detectable tumor.  In those that do, however, it is conceivable that 
morphologic manifestations of a paraneoplastic process might be visible in routine 
microscopic examination of the tumor itself; specifically, altered immune cell populations 
and altered neuroglial elements.  Few studies have evaluated the histopathology of 
NMDAR encephalitis-associated (NMDAR-E) teratomas.[2, 7-13]  The topography and 
composition of immune cell populations in these tumors (B lymphocyte-rich infiltrates 
and lymphoid aggregates with germinal centers localized in and around neuroglial 
elements) and the demonstration of NMDAR expression within the neuroglial elements 
have been reported as evidence in keeping with an auto-immune model of 
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pathogenesis.   Altered morphology of the neuroglial elements has been described as 
further support of this model.  However, the literature is limited by the scant number of 
studies, by small sample sizes and by differing study designs, making it challenging to 
compare results and leading to some conflicting observations, particularly in comparison 
to control teratomas. 
 
The aim of the current study was to determine whether the morphologic, 
immunophenotypic, and topographic properties of the immune cell populations and the 
neuroglial populations distinguish NMDAR-E teratomas from ovarian teratomas 
containing mature neuroglial elements in women without NMDAR-E (herein referred to 
as control teratomas).  As described by others in smaller series, we hypothesized that 
the presence and topography of B-cell infiltrates and lymphoid aggregates with germinal 
centers in and around neuroglial elements would distinguish the NMDAR encephalitis-
associated ovarian teratomas (NMDAR-E teratomas) from control teratomas.  We also 
hypothesized that the neuroglial and ganglion cell populations in NMDAR teratomas 
would exhibit alterations in cell number, distribution, and/or morphologic and 
immunophenotypic properties compared to control teratomas.  In addition to the 
potential implications for understanding pathogenesis of this syndrome, awareness of 
the gross pathologic and morphologic hallmarks of NMDAR teratomas is valuable to 
diagnostic pathologists because in a minority of instances the neurological 
manifestations of the syndrome develop after an otherwise incidental ovarian teratoma 
is removed.[10, 14]    
 
MATERIALS AND METHODS 
 
Case and control selection 
 
With approval from our institutional review boards, 12 women with NMDAR encephalitis 
who had a concurrent teratoma of the ovary (n=11) or mediastinum (n=1) surgically 
resected were identified from our pathology archives. Ten women underwent surgery at 
University of California San Francisco (UCSF), San Francisco, CA and 2 women 
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underwent surgery at Yale-New Haven Hospital, New Haven, CT.  The criteria for the 
diagnosis of NMDAR encephalitis were based on the clinical evaluation by the treating 
neurologist as documented in the electronic medical record and based on the presence 
of stereotypical symptoms and progression over time.  The clinical diagnosis was 
confirmed by a positive test result for NMDAR antibody titer in the serum and/or 
cerebrospinal fluid in 10 of 10 women who were tested (NMDAR antibody titers were 
not tested in the remaining 2 women).  The time interval between clinical diagnosis and 
oophorectomy was recorded as was the pre-operative use of immunosuppressive 
therapy. 
A control group was formed of women without encephalitis who had an ovarian mature 
teratoma containing neuroglial tissue (so-called control teratoma) removed at UCSF.  
The electronic medical records were reviewed to confirm that none of these patients 
with control ovarian teratoma had concurrent encephalitis.  To establish a case-control 
ratio of 1 to 5, a total of 61 women were included in the control group after microscopic 
examination of consecutive specimens from our pathology archives.   Ovarian 
teratomas lacking any neuroglial tissues were excluded as were tumors that contained 
any component of malignancy.   The control group was also selected to roughly match 
the age distribution of the NMDAR-teratomas.  Thus, about 20% of the cases and of the 
controls were under 18 years old.  
Gross pathologic evaluation 
The size (maximum diameter) of each teratoma was obtained from the pathology report 
gross description; if a tumor was received in fragments, the size described in the pre-
operative radiology report was used.   Gross specimen photographs were available for 
most of the cases to supplement the findings in the gross description.  Cysts were 
classified as simple if they were unilocular, had a smooth inner lining, and were devoid 
of any clear features of teratoma such as hair, sebum, bone and/or cartilage.  
Otherwise, the presence of these grossly visible findings in the cysts was reported as 
consistent with a teratoma.  The presence or absence of a solid fibrofatty nodule 
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7 
emanating from the inner cyst lining (so-called Rokitansky nodule [15]) was recorded; if 
present, the size of the nodule relative to the size of the cyst was also recorded. 
Lymphoid tissue evaluation 
The lymphoid populations were evaluated within and adjacent to neuroglial tissues (both 
CNS-like neuropil and ganglion cell clusters) as well as in areas of non-neural tissue 
and were classified as lymphoid infiltrates, lymphoid aggregates with germinal centers, 
and lymphoid aggregates without germinal centers.  Lymphoid infiltrates, when present, 
were subjectively classified as low-cellularity versus high-cellularity diffuse infiltrates.  
The lymphoid density was also quantified by counting the number of lymphocytes per 
400X total magnification high power fields (hpf) in the areas of highest density in the 
routine hematoxylin and eosin (H&E) stained slides.  In selected tumors with a high 
lymphoid density, cell counts per hpf were also conducted using immunohistochemically 
stained slides with the following antibodies:  CD20, CD3, CD138, and FOXP3 (a marker 
of both natural T regulatory cells (nTregs) and adaptive / induced T regulatory cells (a / 
iTregs)).  In addition, the number of lymphoid aggregates was determined by counting 
all lymphoid aggregates (arbitrarily defined as clusters of 50 or more lymphocytes) 
adjacent to neuroglial or non-neural tissues; lymphoid aggregates with germinal centers 
were identified based on the presence of large cells in the center of the aggregate. 
Neuroglial tissue evaluation 
Neuroglial tissue was categorized into two populations:  a.) central nervous system 
(CNS) - like neuropil usually containing neurons (cells with large nuclei, open chromatin, 
prominent nucleoli, and variable Nissl substance), astrocytes (cells with indistinct 
cytoplasm and oblong nuclei with granular chromatin), and oligodendrocytes or b.) 
ganglion cell clusters (large neurons resembling dorsal root ganglia, surrounded by 
satellite cells) not associated with neuropil.  The amount of all neuroglial tissues in each 
teratoma was approximated by calculating the percentage of the total surface area of 
tumor in each slide occupied by neuroglial tissue.  The number of tissue sections 
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containing neuroglial tissue was recorded. A tissue section was defined as a single 
specimen slice; in most cases each glass slide contained a single tissue section, but 
some contained more than two or more tissue sections.  
 
The density of individual cell types per high power field within neuroglial tissue was 
calculated on routine H&E stained slides.  In selected cases and controls with the 
highest lymphoid density, the cell counts were also performed on 
immunohistochemically stained slides using the following antibodies: NeuN (a marker of 
mature neurons), MAP2 (a marker of mature neurons, glial precursor cells, and some 
neoplastic glial cells) and OLIG2 (a marker of oligodendrocytes). 
 
Immunohistochemical methods 
 
Staining for NeuN (A60, Chemicon, 1:4000), MAP2 (microtubule-associated protein 2, 
HM2, Sigma, 1:20,000), CD20 (MJ1, Leica, prediluted), CD3 (LN10, Leica, prediluted), 
and CD138 (MI15, Leica, prediluted) was performed in our clinical laboratory on the 
Leica BOND III automated immunohistochemistry platform using a range of epitope 
retrieval incubation times (from 0-30 minutes).  Staining for FOXP3 (1:50, 
ABCAM20034), was performed on the Ventana Benchmark XT platform in the UCSF 
Brain Tumor SPORE Tissue Core (NIH/NCI P50 CA097257). Unstained slides for the 
FOXP3 staining were deparaffinized, unmasked with a Tris-based buffer at a pH of 8.5 
for 30 minutes, exposed to hydrogen peroxide for 8 minutes, incubated with the primary 
anti-FOXP3 antibody for one hour, then visualized with secondary immunoreagents and 
DAB substrate and counterstained.   
 
Statistics 
 
All data were analyzed with GraphPad Prism 7 statistical software. For evaluating 
normality, both the D'agostina-Pearson omnibus and the Shapiro-Wilk tests were used. 
To be considered non-parametric, the distribution had to exhibit an alpha <0.01 for both 
tests. Difference in variance was determined using an F test. Statistical significance 
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between groups was determined using a two-tailed t-test if the data was normally 
distributed. If there was a significant difference in variance between groups, Welch's 
correction was added to the two-tailed t-test. If data were non-parametric, a Mann-
Whitney U test was used. A Fischer’s exact test was used to analyze the proportion of 
cases with and without a specific pathology.  Statistical significance was defined as 
p<0.05. 
 
RESULTS 
 
Clinical presentation 
 
The average age of the 12 women with an NMDAR-E teratoma was 25 years (range, 13 
to 36 years); two of the 12 (20%) were younger than 18.  By design, the women in the 
control group had a similar age distribution (average age 26 years, range 4 to 48).      
The symptoms developed over the course of weeks to months, initially presenting with 
prodomal fever and/or persistent headache (5/12 women), followed by abrupt onset of 
erratic mood, speech and behavior (10/12) and visual/auditory hallucinations (6/12).  
These symptoms eventually progressed to seizures and respiratory failure requiring 
mechanical ventilation in 10 of 12 women; 9 of these 10 women initially presented to 
another hospital where they were first managed in an intensive care unit environment 
for a median of 22.5 days (range 5 to 72 days) before transfer to one of our hospitals.   
Seven of these 9 women were intubated during the initial hospitalization, including 4 of 
whom had prolonged ventilator-dependency leading to tracheostomy prior to transfer.  
The diagnosis of autoimmune encephalitis was pursued at the original hospital in 4/9 
women; for the remainder, the diagnostic considerations included infectious meningitis, 
central nervous system lymphoma, seizure disorder, and/or schizophrenia.   Two of the 
12 women initially presented directly to our hospital with altered mental status and 
bizarre behavior but without seizures or respiratory failure.   
 
At the time of presentation at our hospitals, NMDAR encephalitis was considered as a 
possibility in each patient and pelvic imaging was performed to evaluate for ovarian 
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teratoma.  Radiologic evidence of an ovarian cyst or mass was present in 9/11 women 
whereas a mediastinal mass consistent with teratoma was identified in 1 woman, whose 
ovaries were radiologically normal.   The median time interval from radiologic detection 
of the teratoma to surgery was 1.5 days for the 9 women with an ovarian teratoma; the 
woman with a mediastinal teratoma presented with symptoms limited to memory loss 
and mild mood alterations, and her surgery occurred 24 days after radiologic detection.  
Pre-operative immunosuppressive therapy (steroids, plasmapheresis, Rituximab, and/or 
intravenous immunoglobulin) was administered in 10/12 women without significant 
immediate effect on neurologic status pre-operatively.     
 
The surgical procedures were unilateral oophorectomy with or without salpingectomy 
(10 women), unilateral ovarian cystectomy (1 woman), and mediastinal tumor resection 
(1 woman).   Intraoperatively, the ovary appeared cystic (7 women) or normal (3 
women); the intraoperative appearance of the ovary was not reported for 1 woman. In 
the 1 woman with a mediastinal teratoma, the tumor arose in the left anterior 
mediastinum.   
 
Post-operatively, only 1 of the women requiring pre-operative mechanical ventilation 
improved to the point of extubation within a few days after surgery.   Most of the rest 
experienced slowly improving but persistent autonomic storming and remained 
ventilator-dependent at the time of transfer to a rehabilitation hospital at a median of 27 
days (range 3 to 180 days) after surgery; one patient died of toxic megacolon 83 days 
after surgery.   Median post-discharge follow up time was 33 months (range 2.4 to 88 
months).  One woman required continued hospitalization. The remainder regained 
autonomic stability, although only one woman returned to her baseline cognitive 
function and the majority continued to experience mild to moderate degrees of residual 
neurologic impairment.  
  
Gross pathology 
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The clinical diagnosis of NMDAR encephalitis was communicated to the pathologist at 
the time the surgeon submitted the specimen for pathologic evaluation in 10/12 women.  
In the remaining two women, the submitted clinical history was chronic respiratory 
failure in one woman and a symptomatic ovarian follicular cyst in the other woman.   
The ovarian teratoma was unilateral in all 11 women; in contrast, 20% (12/61) of the 
women in the control group had bilateral ovarian teratomas.  The specimen was an 
intact ovary containing cysts in 9/11 women whereas in the other two women the 
specimen consisted of multiple fragments of cyst in wall (Figs. 1-3).  In 7/11 specimens, 
the teratoma was predominantly composed of a Rokitansky nodule that nearly 
completely filled the cyst, leaving only a compressed rim of space containing sebaceous 
material around the nodule.  For this reason, these 7 tumors grossly appeared more 
solid than cystic, although most of these specimens also contained multiple simple cysts 
in the ovarian parenchyma adjacent to the teratoma (these corresponded to follicle 
cysts on microscopic examination).  Hair emanating from the surface of this nodule was 
present in 5/7 specimens, two of which also contained cartilage or bone.  Among the 4 
specimens without a Rokitansky nodule, the specimen consisted of fragmented cyst 
walls with matted hair and sebum in 1 woman.  In the remaining 3 women, the 
specimen was an intact ovary containing multiple simple, smooth lined cysts without any 
hair, sebum, cartilage or bone to suggest a teratoma.  Among the control teratomas, 
22/61 consisted of an intact cyst and the remainder were fragmented.  A Rokitansky 
nodule was present in 49/61 control teratomas.  Nearly all of the control teratomas 
contained hair and sebaceous material while half contained bone or cartilage. 
The median size of the NMDAR-E teratomas was 1.7 cm (range 0.7 to 5 cm), which 
was significantly smaller than that of the control teratomas (Table 1).  The specimens 
were entirely examined microscopically in 9/12 women; representative sampling for 
microscopic examination was performed in 3/12 women.   On average 8 cassettes of 
tissue were examined microscopically (range 3 to 15 cassettes).   Paratubal cysts were 
visible in the fallopian tube of 4 of the 6 women who also underwent salpingectomy.  
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In the woman with a mediastinal teratoma, the specimen consisted of a 4.1 cm intact 
multicystic mass containing cartilage but no hair or sebaceous material (Fig. 3B).  
 
Microscopic pathology 
 
All 12 NMDAR-E teratomas contained neuroglial tissue as well as non-neuroglial 
tissues, the most common being keratinizing squamous epithelium, sub-cutaneous 
adnexal structures and adipose tissue, mucinous epithelium, and various mesenchymal 
tissues.  In 11/12 NMDAR-E teratomas the neuroglial tissues were mature and in 1 
tumor there was also a single microscopic focus of immature neural elements; in the 
latter case, the scant size did not meet criteria for classification as an immature 
teratoma.[16]   The neuroglial tissues comprised only a small area of each tumor (Table 
1); however, the neuroglial tissue represented a larger percentage of the total tumor in 
the NMDAR-E teratomas compared to the control teratomas (Table 1, Supplementary 
Fig.S1).  Neuroglial tissue was not present in the frozen section samples of the two 
NMDAR-E teratomas that were evaluated intraoperatively. 
 
There were two patterns of distribution of the neuropil-associated neuroglial tissue in the 
NMDAR-E teratomas.  The first pattern, which was present in all 12 tumors, was a 
unifocal or multifocal solid irregularly shaped area of neuropil embedded within the 
center of the adipose tissue of the Rokitansky nodule (Fig. 4).  In some cases, the 
neuropil was surrounded by small foci of bone, cartilage, and/or mucinous glandular 
elements.  The second pattern (Fig. 5), which was present in 4/12 NMDAR-E teratomas, 
consisted of thin subependymal bands of neuropil along the wall of a cyst, recapitulating 
a ventricle of the central nervous system (also referred to as a glial cyst in older 
literature[15]).  Ependyma lined the cyst walls.  Tubulo-glandular ependymal structures 
were also embedded within the solid pattern component of neuropil in 4/12 NMDAR-E 
teratomas.   
   
Compared to control teratomas, neuropil-associated neuroglial tissue in the NMDAR-E 
teratomas contained a paucity of mature neurons and a hypercellular population of 
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astrocytes.   Whereas control teratomas contained 7 mature pyramidal neurons per high 
power field of neuropil, only 1 mature neuron per high power field of neuropil was 
present in NMDAR-E teratomas (Table 1, Fig. 6).  In addition, these few remaining 
neurons often exhibited degenerative changes, such as shrunken or smudged nuclear 
contours, vacuolation of the cytoplasm, and variable chromatolysis (Fig. 6A-B).  The 
relative absence of mature neurons in NMDAR-E teratomas was confirmed by NeuN 
immunohistochemistry (Table 1, Fig. 7A, D, G).  Although the overall density of MAP2-
positive cells was similar in NMDAR-E teratomas and control teratomas (Fig. 7H), there 
was no significant subpopulation of MAP2-positive (MAP2+) cells that correlated to the 
morphology of mature pyramidal neurons in NMDAR-E teratomas.  In control teratomas, 
MAP2 immunohistochemistry typically labeled the cytoplasm of mature neuron-like cells 
with a granular background of staining in dendritic processes (Fig. 7B). In the NMDAR-E 
cases, on the other hand, MAP2 labeled the cytoplasm of small cells with stubby 
processes, with only focal granular background staining  present (Fig. 7E); these cells 
were visible on the MAP2-stained slides, but their correlate was not apparent on the 
H&E stained slides.     
 
Astrocytes were present at a higher density in NMDAR-E teratomas (Table 1, Fig. 8) 
and they also often exhibited striking dysmorphic alterations ranging from nuclei with 
hyperchromasia, enlargement and irregular contours, to large multinucleated cells with 
abundant gemistocytic cytoplasm or cells filled with abundant eosinophilic deposits. 
Reactive changes (including variable Rosenthal fibers and gemistocytic morphologies) 
were occasionally also observed in control teratomas.  Oligodendrocytes were present 
to the same extent in NMDAR-E teratomas and control teratomas, as evaluated using 
OLIG2 immunohistochemistry (Fig. 7C, F, I).   
 
Ganglion cell clusters were present in 5/12 (42%) of NMDAR-E teratomas but only in 
10/61 (16%) of control teratomas (Table 1, Fig. 9).  The total number of ganglion cell 
clusters ranged from 0 to 9 in the NMDAR-E teratomas and 0 to 7 in the control 
teratomas (Fig. 9E).  None of the ganglion cell clusters were embedded within neuropil, 
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but in rare instances they were located in immediate proximity.  None exhibited striking 
nuclear atypia or degenerative changes. 
Diffuse lymphoplasmacytic infiltrates were present within neuropil-associated neuroglial 
tissue in 4/12 (25%) of NMDAR-E teratomas and in 26/61(43%) of control teratomas 
(Table 1, Supplementary Fig. S2).  The ganglion cell clusters were rarely involved by 
these infiltrates in either type of teratoma.  The overall lymphocyte density in neuroglial 
tissue was only slightly increased in NMDAR-E teratomas compared to control 
teratomas on routine H&E stained slides (Table 1, Supplementary Fig. S2); there was 
no difference in the density of B-cells, plasma cells, T-cells, or regulatory T-cells using 
immunohistochemistry (Table 1, Supplementary Fig. S2). 
Lymphoid aggregates without germinal centers were present adjacent to neuropil-
associated neuroglial tissue in all 12 NMDAR-E teratomas and were present adjacent to 
ganglion cell clusters in 4/5 (80%) NMDAR-E teratomas containing ganglion cell 
clusters (Table 1).  The median number of lymphoid aggregates without germinal 
centers near neuroglial tissue was 3 per tumor.  In contrast, lymphoid aggregates 
without germinal centers were present near neuropil-associated neuroglial tissue in 
43/61 (70%) control teratomas and the median number of aggregates was 1 per tumor 
(Fig. 4H).   Among the 9 control teratomas with ganglion cell clusters, adjacent lymphoid 
aggregates without germinal centers were only present in 1 tumor (Fig. 9G).  
Lymphoid aggregates with germinal centers were more strongly associated with 
NMDAR-E teratomas.  These were present surrounding neuropil-associated neuroglial 
tissue in 11/12 (92%) NMDAR-E teratomas but only in 4/61 (7%) control teratomas.  In 
the NMDAR-E teratomas, the median number of these lymphoid aggregates with 
germinal centers was 3 per tumor, ranging from 0 in one tumor up to 7 in total in another 
tumor, while the median number of lymphoid aggregates with germinal centers was 0 in 
control teratomas (Fig. 4G).  Among the 5 NMDAR-E teratomas containing ganglion cell 
clusters, only 2 exhibited adjacent lymphoid aggregates with germinal centers; none 
were found in the 9 control teratomas with ganglion cell clusters (Fig. 9F). 
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Non-neural teratomatous tissue (e.g. keratinizing squamous epithelium, cutaneous 
adnexal structures, mucinous glandular elements) was involved by diffuse 
lymphoplasmacytic infiltrates in 1/12 (8%) NMDAR-E teratomas and in 11/61 (18%) 
control teratomas (Table 1, Supplementary Fig. S3).   Lymphoid aggregates without 
germinal centers involving non-neuroglial tissue were present in 11/12 NMDAR-E 
teratomas and in all 61 control teratomas.  Lymphoid aggregates with germinal centers 
were present adjacent to non-neuroglial tissue in 5/12 (42%) NMDAR-E teratomas and 
in 15/61 (25%) control teratomas. Lymphoid aggregates without germinal centers were 
actually higher in control teratomas, likely due to the greater amount of non-neural 
tissue in these teratomas. 
Non-teratomatous pathology 
The non-neoplastic ovarian cortex adjacent to the NDMAR-E teratoma exhibited the 
expected appearance for a premenopausal ovary:  oocytes in primordial, primary and 
secondary follicles; corpus luteum and corpus albicans (Supplementary Fig. S4).  
Multiple follicle cysts were present in 7/11 ovary specimens and epithelial inclusion 
glands or cysts were present in 4/11.  A mucinous cystadenoma associated with 
intestinal-type teratomatous elements was present in 1 of the NMDAR-E teratoma 
specimens.  There were no inflammatory infiltrates or lymphoid aggregates in the 
ovarian parenchyma or involving the fallopian tubes.  Paratubal cysts were present in 
4/6 salpingectomy specimens. 
DISCUSSION 
This study of 11 ovarian teratomas and 1 mediastinal teratoma in women with NMDAR 
encephalitis demonstrates alterations in the immune cell and neuroglial populations that 
are not present in control teratomas and therefore further substantiate the paradigm of a 
paraneoplastic mechanism for the encephalitis.  Specifically, NMDAR-E teratomas were 
characterized by 1.) the presence of lymphoid aggregates with germinal centers around 
neuroglial tissue; 2.) the near absence of mature neurons within neuropil; and 3.) the 
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presence of hypercellular astrocyte populations.  These observations carry practical 
implications for the pathologic evaluation of ovarian teratoma specimens as well as 
implications for understanding the mechanism of this syndrome. 
 
Although more than five hundred cases have been reported since the syndrome of 
NMDAR encephalitis associated with ovarian teratoma was first described in 2005,[2, 3] 
there is scant literature on the histopathology of the ovarian teratomas in these patients;  
only 51 cases, excluding the current study, have been described in terms of the immune 
cell and/or neuroglial populations (Table 2).[2, 7-13]  The prevailing theory for 
pathogenesis is that antibody-mediated injury to neurons in the hippocampus and 
prefrontal cortex of the brain is caused by auto-antibodies generated against NMDAR 
on the teratoma that cross the blood brain barrier [5, 6]; a causal relationship is 
suggested by the clinical observation that tumor resection is often followed by reduction 
of auto-antibody titers and clinical improvement.[2]  This theory does not fully explain all 
cases as only about half of patients have a detectable tumor.  The trigger for generation 
of auto-antibodies is not understood; viral infection has been proposed as one possible 
mechanism.[5]  Nor is the mechanism by which the auto-antibodies cross the blood-
brain barrier understood.  Regardless of the initiating event, antibodies to NMDAR can 
be detected in the serum and/or cerebrospinal fluid of these patients.[3]  Neuroglial 
tissues in the associated ovarian teratomas have been shown to express the two 
subunits of  the NMDAR, NR1 and NR2.[2, 7, 9, 12]  NMDAR have also been detected 
within germinal centers of lymphoid aggregates in an ovarian teratoma from the patient 
with this syndrome.[8]  Autopsy brain findings from patients with NMDAR encephalitis 
are notable for regional loss of pyramidal neurons, neuronal degeneration, gliosis, and 
deposition of immunoglobulin in the hippocampus, basal forebrain, basal ganglia and 
spinal cord.[12]  Therefore, a parallel constellation of alterations in the neuroglial and 
immune cell populations might be expected in the associated ovarian teratomas.   
 
In our study, the density of mature neurons was strikingly reduced in NMDAR-E 
teratomas versus control teratomas whether evaluated by routine H&E staining or by 
NeuN staining.  The cause of the relative absence of mature neurons in the NMDAR-E 
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teratomas is not clear; one potential explanation is that this represents the end stage 
result of sustained autoimmune injury to the neurons.  In that case, a spectrum of 
damage ranging from varying degrees of degenerative changes to cell loss might be 
expected.  One study has described degenerative changes in the neurons of two 
NMDAR-E teratomas [10], and indeed the few remaining neurons identified in this study 
often demonstrated shrunken or smudged nuclear contours, vacuolation of the 
cytoplasm, and variable chromatolysis. The increased density of astrocytes along with 
the dysmorphic/reactive features observed in this study could also reflect a prominent 
response to neuronal injury.  
A response to neuronal injury might also explain the small cells with stubby processes 
that exhibit a MAP2+ / NeuN-negative (NeuN-) immunophenotype in the NMDAR-E 
teratomas.  While mature neurons exhibit well-formed dendrites and a dual MAP2+, 
NeuN+ immunophenotype, these small cells with stubby processes may represent 
injured, degenerating neurons, in keeping with the autoimmune paradigm for this 
syndrome.  In support of this interpretation, a similar loss of  a NeuN+ 
immunophenotype has been described following neuronal injury in studies of axotomy 
and excitotoxicity.[17, 18]  A second possibility comes from the observation that some 
neoplastic astrocytes can exhibit a similar morphology and immunophenotype, though it 
is unclear how such cells would fit into an autoimmune paradigm.[19]  Dysplastic 
neuronal alterations similar to gangliogliomas have been described in a study of 4 
NDMAR teratomas.[11]   The criteria for defining dysplastic alteration were 
multinucleation, dysmorphic cell shape, and a clustered distribution of neurons; none of 
these features were definitively observed in the current study nor did any of the 
neuroglial tissue resemble a neuronal or glioneuronal neoplasm.  We did however note 
occasional striking dysmorphic features in the astrocyte population including 
multinucleation. A third possibility comes from the observation that some glial and 
neuronal precursors exhibit the morphology of small cells with stubby processes and 
MAP2+, NeuN- immunophenotype.[19]   Therefore, if MAP2+, NeuN- cell population in 
NMDAR-E teratomas represents a type of immature cell unique to this tumor syndrome, 
then it is conceivable that antigens on those cells could be responsible for triggering the 
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abnormal immune response to NMDAR.  Of note, immature teratomas comprise up to 
26% of the teratomas associated with NMDAR encephalitis, although none were 
observed in the current study.[1]  Oncofetal antigens expressed by a variety of 
neoplasms are known to induce strong immune responses.[20]   In particular, many 
paraneoplastic syndromes are associated with embryonal antigens expressed by 
pulmonary small cell carcinoma.[21]   The nature of this distinct population of MAP2 
positive / NeuN negative small cells merits further study, particularly with respect to its 
potential role in pathogenesis of this syndrome. 
Similarly, the hypercellular astrocyte populations observed in the NDMAR-E teratomas 
but not in the control teratomas deserves further investigation.  One study reported an 
abnormal glial population in 2 NMDAR-E teratomas, characterized by hypercellularity 
and, in 1 of 2 tumors, elevated proliferative activity measured by Ki-67 
immunohistochemistry.[11]  Whether the MAP2+, NeuN- small cells in the current study 
correlate with the abnormal glial population described by others is difficult to address 
because the earlier study did not evaluate MAP2 or NeuN staining. 
Regarding the immune cell populations in NMDAR-E teratomas, our study validates the 
prior observation that co-localization of neuroglial tissue and lymphoid aggregates with 
germinal centers is a distinct feature that is not commonly present in control 
teratomas.[10]   As reported for 3 of 5 NMDAR-E teratomas in that study, all but one 
NMDAR-E teratoma in the current study exhibited numerous lymphoid aggregates with 
germinal centers adjacent to neuropil-associated neuroglial tissue.  Although similar 
findings were seen in a minority of control teratomas, the total number of lymphoid 
aggregates with germinal centers per tumor was significantly higher in the NMDAR-E 
teratomas.  A recent study demonstrated that antibodies to the NMDAR subunits NR1 
and NR2 can be detected within the germinal centers of such lymphoid aggregates; this 
suggests that the lymphoid aggregates neighboring the neuroglial tissues may be 
responsible for generating the auto-antibodies to NMDAR.   
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None of the other immune cell populations, such as diffuse infiltrates involving 
neuroglial tissue, specific subsets of immune cells (T-cells, regulatory T cells, B cells or 
plasma cells), or lymphoid aggregates without germinal centers, were as significantly 
associated with NMDAR-E teratomas in this study.  Three studies reported increased 
immune cell populations (specifically B-cell populations in two of the three studies) 
involving neuroglial tissue in NMDAR-E teratomas compared to control teratomas.[7, 
11, 12]  Most of the patients in the current study were treated with immunosuppressive 
therapy prior to oophorectomy.  It is possible that this may have diminished the immune 
cell populations in the NMDAR-E teratomas just enough such that any natural difference 
compared to control teratomas was not detectable; nevertheless, the presence of 
lymphoid aggregates with germinal centers remained a striking difference between the 
two teratoma types. 
The practical implications of this study are two-fold.  First, NMDAR-E teratomas may not 
exhibit significant ovarian enlargement or cystic features when viewed intraoperatively 
or grossly prior to dissection; the size of the tumor may be under 1 cm and on average 
is just under 2 cm.  The small size is most likely due to the fact that these tumors were, 
by definition, asymptomatic in terms of the typical presentation of an ovarian cyst.  
Instead, these clinically occult tumors were detected only by radiologic screening as 
part of the work-up and management of NMDAR encephalitis.   Even after specimen 
dissection, the cysts of NMDAR-E teratomas may occasionally be simple in gross 
appearance, without any specific features to suggest teratoma such as hair, sebum, 
cartilage or bone.   Furthermore, large follicle cysts, occasionally the same size as the 
cystic teratoma, were also present in the majority of specimens in this study.  Therefore, 
if the clinical history is suggestive of NMDAR encephalitis, the ovarian specimen should 
be thinly sliced in its entirety to look for evidence of any teratoma.   If the gross findings 
are equivocal for evidence of a teratoma, complete submission of the entire ovary for 
microscopic examination is advised.  Complete submission of the entire ovary should be 
considered even if there is gross evidence of teratoma, because the presence of 
neuroglial tissue may be limited to only one or two tissue sections of the entire 
specimen.  In our study, the neuroglial tissues were most often embedded in adipose 
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tissue in the center of the Rokitansky nodule, as has been recognized by others as long 
as a century ago.[22-24]   Therefore, at a minimum, tissue sampling should focused on 
the Rokitansky nodule.  In a minority of cases in our study, neuroglial tissue was also 
present in a subependymal band-like distribution in cystic structures recapitulating 
ventricles.  This has also been described by others and sometimes referred to as a glial 
cyst.[15, 23, 24]   In our study, lymphoid aggregates with germinal centers was present 
in these areas as well.   Thus, cyst-like areas also merit microscopic attention for 
possible neuroglial tissues.  Finally, if the microscopic findings of a representatively-
sampled ovary from a woman with suspected NMDAR encephalitis confirm a diagnosis 
of teratoma but neuroglial tissues are not identified, submission of the remaining tissue 
for microscopic examination is advised in an attempt to identify neuroglial tissue and 
evaluate for the presence of nearby lymphoid aggregates with germinal centers.   
Though this may not necessarily be essential to clinical care, documenting such findings 
is important for clinicopathologic correlation, particularly if the results of NMDAR 
antibody titers are still pending. 
 
The second practical implication is that in the pathologic reporting of any ovarian 
teratoma, it may be of clinical value to document the presence of co-localized neuroglial 
tissue and lymphoid aggregates with germinal centers, even if there is no history of 
NMDAR encephalitis.  At least two patients with NMDAR encephalitis have been 
reported to develop the onset of symptoms at a time point after an otherwise incidental 
removal of an ovarian teratoma.[10, 14]   Therefore, alerting the clinician to the 
presence of this finding may be valuable to prompt immediate clinical correlation with 
the patient’s neurological status and to prompt consideration of this syndrome if the 
patient develop prodromal symptoms at a later time.  Because the early symptoms of 
NMDAR encephalitis are not specific, there is a broad differential diagnosis to consider; 
in fact, as reported in the literature and in our study, NMDAR encephalitis is often not 
among the leading clinical considerations, particularly in patients who are first managed 
by providers other than neurologists or mental health providers.[3]  Early diagnosis of 
the syndrome before progression to severe symptoms and early intervention with 
immunotherapy are associated with a more favorable outcome.[3]  By documenting the 
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presence of this relatively distinct morphology, the pathologist has an opportunity to 
contribute to early intervention in the, albeit rare, setting of post-oophorectomy onset of 
NMDAR encephalitis. 
In summary, NMDAR-E teratomas are characterized by co-localization of neuroglial 
tissue and lymphoid aggregates with germinal centers, a finding that is uncommon in 
control teratomas.  These tumors exhibit a relative paucity of mature neurons and a 
hypercellular astrocyte population.  How these alterations in neuroglial cell populations 
are related to the pathogenesis of NMDAR encephalitis merits further study. 
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FIGURE LEGENDS 
Figure 1 
On initial gross examination, some NMDAR-E teratomas appeared normal (A) and did not 
contain obvious features of a teratoma (B), though simple cysts were present.  A small nodule 
(B, arrow) corresponded to a Rokitansky nodule (C, arrow), within which neuroglial tissue (C, 
arrowhead) was surrounded by adipose and cutaneous teratomatous elements.  Some 
NMDAR-E teratomas were mildly enlarged (D) and contained multiple follicle cysts (E), but no 
obvious features of a teratoma.  A small nodule (E, arrows) corresponded to a Rokitansky 
nodule (F, arrow), within which was neuroglial tissue surrounded by adipose and cutaneous 
teratomatous elements.    
Figure 2 
Most NMDAR-E teratomas consisted of a 1 to 2 cm hair-bearing Rokitansky nodule within a cyst 
(A); the neuroglial tissue was located in the center (B, arrow) or in a subependymal distribution 
along cyst walls (B, arrowheads).   In some cases, the Rokitansky nodule nearly obliterated the 
cyst cavity (C, D; arrow indicates neuroglial tissue) or entirely filled the cyst, resulting in a solid 
appearance (E, arrow; F, arrow).  The adjacent cyst (E, arrowheads) was a mucinous 
cystadenoma (F, double arrowheads).  The neuroglial tissue was in the center of the Rokitansky 
nodule (F, single arrowhead). 
Figure 3 
A minority of the NMDAR-E teratomas were cystic without a discrete Rokitansky nodule; one 
case exhibited typical features of matted hair, sebaceous material, fat and cartilage (A).  The 
mediastinal NMDAR-E teratoma was predominantly solid and fleshy with focal cystic features 
(B).  
Figure 4 
Neuropil-associated neuroglial tissue (A, arrow) was present in the center of the Rokitansky 
nodule in each of the NMDAR-E teratomas and was surrounded by a variable number of 
lymphoid aggregates containing germinal centers ranging from numerous confluent aggregates 
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to just a few (B to F). Lymphoid aggregates with germinal centers surrounding neuropil were 
more frequent in NMDAR-E teratomas compared to control teratomas (G).  In contrast, 
lymphoid aggregates that lack germinal centers were present adjacent to neuropil to the same 
extent in both groups of teratomas (H). Each tumor is represented with a symbol; solid lines 
indicate the median and 95% confidence interval (****, p<0.001; ns, not significant). 
Figure 5 
In some cases of NMDAR-E teratoma, neuroglial tissue was located beneath a layer of 
ependyma lining the wall of a cyst (so-called glial cyst) (A to F).  The cyst was located either 
within (A) or adjacent (B) to the Rokitansky nodule.  Choroid plexus was often present (E).  
Lymphoid aggregates with germinal centers were present (E, F).   
Figure 6 
Mature neurons were rare and showed degenerative features within neuropil in NMDAR-E 
teratomas (A, B) compared to control teratomas (C,D).  Degenerative features included 
shrunken neuronal nuclei with smudged contours  and cytoplasmic vacuolation (A, black 
arrowhead), and chromatolysis (A, blue arrowhead; B, black arrowhead). The cellularity of 
mature neurons within the CNS-like neuropil was significantly lower in NMDAR-E teratomas (E). 
Each tumor is represented with a symbol; solid lines indicate the median and 95% confidence 
interval (***; p<0.001). Scale bars, 50 μm. 
Figure 7 
Immunostaining for neural markers highlights differences in neural cell populations in NMDAR-E 
teratomas versus control teratomas.  NeuN positive mature neurons were rare in NMDAR-E 
teratomas (A) compared to control teratomas (D); the difference was statistically significant (G).  
MAP2+ small cells with blunted process were frequent in NMDAR-E teratoma (B).  The 
cellularity of MAP2+ cells in control teratomas (E) was the same (H) but these cells had normal 
dendritic processes rather than blunted processes.  The cellularity of OLIG2+ oligodendrocytes 
in NMDAR-E teratomas (C) and in control teratomas (F) was similar (I). In G-I, each evaluated 
tumor is represented with a symbol; solid lines indicate the median and 95% confidence interval 
(**, p<0.01; ns, not significant). Scale bars, 50 μm. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
25 
Figure 8 
Astrocytes were hypercellular in NMDAR-E teratomas (A-C) compared to control teratomas (D-
F) and exhibited unusual dysmorphic features such as hyperchromasia and mild pleomorphism 
(A), multinucleation (B), or abundant eosinophilic deposits (C).  Such features were not present 
in control teratomas, although some exhibited Rosenthal fibers (E) or gemistocytic features (F). 
The cellularity of astrocytes was significantly higher in NMDAR-E teratomas (G). Each tumor is 
represented with a symbol; solid lines indicate the median and 95% confidence interval (****; 
p<0.0001).   Scale bars, 50 μm. 
Figure 9 
Ganglion cell clusters were equally present in NMDAR-E teratomas (A, B) and in control 
teratomas (C, D).  While scattered lymphocytes were present in and around ganglion cell 
clusters in both groups of teratomas, lymphoid aggregates with germinal centers were present 
in a subset of NMDAR-E teratomas (A) but not in any of the control teratomas (C).  There was 
no difference in the number of ganglion cell clusters between the two groups of teratomas (E). 
Ganglion cell cluster-associated lymphoid aggregates were equally present in NMDAR-E 
teratomas as in control teratomas, regardless of whether germinal centers were present (F, G). 
Each tumor is represented with a symbol; solid lines indicate the median and 95% confidence 
interval (ns, not significant). Scale bars, 50 μm.   
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Supplementary Figure S1. 
Neuroglial tissue was more abundant in the NMDAR-E teratomas compared to control 
teratomas. Each tumor is represented with a symbol; solid lines indicate the median and 95% 
confidence interval. (**, p<0.01) 
Supplementary Figure S2. 
Lymphoplasmacytic infiltration of neuroglial tissue. A-C) Inflamed neuroglial tissue from a 
representative encephalitis-associated teratoma; H&E stain (A), T-cell marker CD3 (B), 
regulatory T-cell marker FOXP3 (C), B-cell marker CD20 (D), and plasma cell marker CD138 
(E). F-J) Inflamed neuroglial tissue from a representative control teratoma; H&E stain (F), T-cell 
marker CD3 (G), regulatory T-cell marker FOXP3 (H), B-cell marker CD20 (I), and plasma cell 
marker CD138 (J). K) The maximum density of lymphocytes is slightly increased in NMDAR-E 
teratomas compared to control cases; however, the density of CD3-positive T-cells (L), FOXP3-
positive regulatory T-cells (M), CD20-positive B-cells (N), and CD138-positive plasma cells (O) 
did not significantly differ between the two groups. Each evaluated tumor is represented with a 
symbol; solid lines indicate the median and 95% confidence interval (K, O) or the group mean 
and SEM (L-N). (**, p<0.01; ns, not significant) Scale bars, 50 μm. 
Supplementary Figure S3. 
Lymphoid aggregates in non-neural tissues. A-B) Representative images of lymphoid 
aggregates with and without germinal centers adjacent to non-neural tissues including adnexal 
structures and mucinous epithelium in NMDAR-E teratomas. C-D) Representative images of 
lymphoid aggregates with and without germinal centers adjacent to non-neural tissues in control 
teratomas. E) The number of germinal centers involving non-neural tissues is similar between 
the two groups. F) The number of lymphoid aggregates without germinal centers is slightly 
higher in the control group, likely secondary to the larger tumor size. Each evaluated tumor is 
represented with a symbol; solid lines indicate the median and 95% confidence interval. (**, 
p<0.01; ns, not significant) Scale bars, 50 μm. 
Supplementary Figure S4. 
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The follicles, oocytes, and ovarian stroma (A to C) appeared normal in the NMDAR-E 
teratomas, without any lymphocyte infiltrate or lymphoid aggregates.  Most of these women also 
had multiple follicle cysts (D). 
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Table 1    
NMDAR-E Teratomas Control Teratomas p-value
Overall tumor size 1.9 cm  7.5 cm  <0.0001 
Neuroglial Population 
Total surface area of neuroglial tissues  0.1 cm2  0.5 cm2 <0.001 
Percent of teratoma composed of neuroglial tissues 5.2%   1.3%   <0.01 
Mature neurons per hpf of neuropil 1  7   <0.001 
Astrocytes per hpf of neuropil 200  97 <0.0001 
Presence of ganglion cell clusters 5/12 (42%) tumors 10/61 (16%) tumors NS 
Ganglion cell clusters per tumor  0  0   NS 
NeuN positive cells per hpf of neuropil 0  18  <0.01 
MAP2 positive cells per hpf of neuropil  19  20  NS 
OLIG2 positive cells per hpf of neuropil  17 ± 3*  24 ± 9*   NS 
Immune Cell Population involving Neuroglial Tissue 
Presence of diffuse lymphoplasmacytic infiltrates 4/12 (33%) tumors 26/61 (43%) tumors NS 
in neuropil 
Diffuse lymphoplasmacytic infiltrate in neuropil 30 14 <0.05 
(cells/hpf) 
Presence of lymphoid aggregates without 
germinal centers around neuropil 12/12 (100%) tumors 43/61 (70%) tumors <0.05 
Presence of lymphoid aggregates without 
Tables
germinal centers around ganglion cell clusters 4/5 (80%) tumors 1/9 (11%) tumors <0.05 
Lymphoid aggregates without germinal centers 3 1 NS 
around neuropil (number per tumor) 
Lymphoid aggregates without germinal centers  2 0 NS 
around ganglion cell clusters (number per tumor) 
Presence of lymphoid aggregates with 
germinal centers around neuropil 11/12 (92%) tumors 4/61 (7%) tumors <0.0001 
Presence of lymphoid aggregates with 
germinal centers around ganglion cell clusters 2/5 (40%) tumors 0/9 (0%) tumors NS 
Lymphoid aggregates with germinal centers 3 0 <0.0001 
around neuropil (number per tumor) 
Lymphoid aggregates with germinal centers  0 0 NS 
around ganglion cell clusters (number per tumor) 
CD20 positive cells per hpf of neuropil 3 ± 1* 3 ± 1* NS 
CD138 positive cells per hpf of neuropil 7 12 NS 
CD3 positive cells per hpf of neuropil 28 ± 8* 23 ± 5* NS 
FOXP3 positive cells per hpf of neuropil 8 ±3* 6 ± 2* NS 
Ratio of CD3 to FOXP3 positive cells 0.38 ± 0.91* 0.25 ± 0.09* NS 
Immune Cell Population involving Non-Neuroglial Tissue 
Presence of diffuse lymphoplasmacytic infiltrates   1/12 (8%) tumors 11/61 (18%) tumors NS 
Presence of lymphoid aggregates without germinal 
centers   11/12 (92%) tumors 61/61 (100%) tumors NS 
 
Lymphoid aggregates without germinal centers  3    10   <0.01 
(number per tumor) 
 
Presence of lymphoid aggregates with germinal 
centers        5/12 (42%) tumors  15/61 (25%) tumors NS 
 
Lymphoid aggregates with germinal centers   0    0   NS 
(number per tumor) 
     
 
 
 
Legend: 
All values represent the median unless indicated by an *, which designates values reported as statistical mean ± standard error of the mean 
NS: not significant (p>0.05) 
hpf: high power field (400X magnification) 
 
  
Table 2  Histopathologic Studies of NMDAR Teratomas 
Study NMDAR-E Control Lymphoid Aggregates  Major Neuroglial Tissue Findings 
Teratomas Teratomas with Germinal Centers  
(n) (n) in Neuroglial Tissue  
(NMDAR-E versus control) 
Current study 12 61 11/12 versus 4/61 Relative absence of mature neurons in NMDAR 
Dalmau et al., 2007 12 0 not studied NR2 detected on neuroglial tissue.   
MAP2 positive immature neurons present. 
Tuzun et al., 2009 9 3 not studied NR1, NR2 detected on neuroglial tissues.  B-lymphocyte 
infiltrates more extensive in NMDAR teratomas  
Cundiff et al. 2015 6 6 not studied NeuN and MAP2 positive cell populations similar in 
NMDAR and control teratomas 
Dabner et al., 2012 5 22 3/5 versus 0/22 Degenerative changes in 2/5 NMDAR versus 0/22 
control teratomas 
Day et al., 2014 4 20 not studied Lymphoid infiltrates around neuroglial tissue in 4/4  
NMDAR teratomas versus 0/20 sporadic teratomas. 
“Dysplastic” neurons in 4/4 NMDAR teratomas versus 
  0/20 control teratomas. 
Clark et al., 2014 5 10 not studied NR1, NR2 detected by immunostains in neuroglial tissue 
and in squamous epithelium of both NDMAR teratomas 
and control teratomas 
Tabata et al., 2014 3 23 not studied Increased B-cell population around neuroglial tissue in  
NMDAR teratomas; NR1 NR2 detected by immunostains 
Makuch et al., 2018 2 0 not studied Antibodies to NR1, NR2 detected in germinal center of 
lymphoid aggregates 
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